EHA26: Epcoritamab improves PFS but not OS in R/R LBCL - Pharmaceutical Technology

The Phase III EPCORE DLBCL-1 met one of the two endpoints, with Genmab set to discuss next steps with global regulatory authorities. The Phase III EPCORE DLBCL-1 met one of the two endpoints, with Genmab set to discuss next steps with global regulatory authorities. Sponsored by Genmab and AbbVie, the EPCORE DLBCL-1 study compared Epkinly (epcoritamab) monotherapy, a subcutaneous CD3×CD20 bispecific antibody, against investigator’s choice chemoimmunotherapy (CIT), either rituximab plus gemcitabine/oxaliplatin or rituximab plus bendamustine. Credit: [ArDanMe]/Shutterstock.com Primary results from the global, randomised, Phase III EPCORE DLBCL-1 (EudraCT 2020-003016-27) trial were presented at the European Hematology Association (EHA) 2026 Congress,…

GlobalData Healthcare · 2026-06-15

The Phase III EPCORE DLBCL-1 met one of the two endpoints, with Genmab set to discuss next steps with global regulatory authorities.

Source: Pharmaceutical Technology